Send to

Choose Destination
Gastric Cancer. 2016 Jul;19(3):902-10. doi: 10.1007/s10120-015-0542-8. Epub 2015 Sep 19.

Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).

Author information

Department of Gastrointestinal Medical Oncology, Shikoku Cancer Center, 160 Minami-Umenomoto Kou, Matsuyama, Ehime, 791-0280, Japan.
Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Cancer Chemotherapy Center, Osaka Medical College Hospital, Takatsuki, Japan.
Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya, Japan.
Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun, Japan.
Division of Gastroenterology, Saitama Cancer Center, Kita-adachi-gun, Japan.
Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.
Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Department of Gastroenterology, Ibaraki Prefectural Central Hospital, Kasama, Japan.
JCOG Data Center/Operations Office, Center for Research Administration and Support, National Cancer Center, Tokyo, Japan.
Department of Medical Oncology and Hematology, Faculty of Medicine, Oita University, Yufu, Japan.
Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.



This randomized phase II study compared weekly administration of paclitaxel (wPTX) with the best available 5-fluorouracil (5-FU) regimen as second-line treatment for advanced gastric cancer patients with severe peritoneal metastasis refractory to fluoropyrimidine.


In the best available 5-FU arm, continuous infusion of 5-FU (800 mg/m(2)/day, days 1-5, every 4 weeks) was given to patients with prior chemotherapy including bolus 5-FU, and methotrexate and 5-FU sequential bolus injection (methotrexate at 100 mg/m(2) followed by bolus 5-FU at 600 mg/m(2) with leucovorin, weekly) was given to those who had previously received continuous infusion of 5-FU or oral administration of fluoropyrimidine. In the wPTX arm, paclitaxel (80 mg/m(2)) was administered on days 1, 8, and 15, every 4 weeks. This study adopted a screening design (one-sided α = 30 %) with the primary end point of overall survival.


One hundred patients were randomized to the 5-FU arm (n = 49) or the wPTX arm (n = 51). Although the median survival time was 7.7 months in both arms, the 2-year survival rates were 2.9 % in the 5-FU arm and 9.1 % in the wPTX arm [hazard ratio 0.89 (95 % confidence interval 0.57-1.38), one-sided p = 0.298}. The median progression-free survival was longer with wPTX than with 5-FU [3.7 months vs 2.4 months; hazard ratio 0.58 (95 % confidence interval 0.38-0.88), one-sided p = 0.005]. The incidences of grade 4 neutropenia, grade 3/4 febrile neutropenia, diarrhea, and treatment-related death were 6 %, 4 %, 10 %, and 2 %, respectively, in the 5-FU arm and 2 %, 0 %, 0 %, and 0 %, respectively, in the wPTX arm.


As second-line chemotherapy, wPTX appears feasible and promising. This regimen can be included in a test arm in future phase III trials for treatment of advanced gastric cancer with severe peritoneal metastasis.


5-Fluorouracil; Gastric cancer; Paclitaxel; Peritoneal metastasis; Phase II study

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center